Previous 10 | Next 10 |
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Rigel Pharmaceuticals Inc. (RIGL) is expected to report $-0.06 for Q3 2023
Rigel to Present at the Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, will pr...
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition PR Newswire -- Growing body of data on REZLIDHIA ® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -...
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will rep...
Rigel Announces Presentation at the Upcoming IDWeek 2023 PR Newswire -- Provides Update on ACTIV-4 Host Tissue Trial -- SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming...
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Induc...
Rigel to Present at the 2023 Cantor Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, wil...
Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief exe...
2023-08-10 17:46:10 ET Summary Rigel Pharmaceuticals shows growth in Q2 2023 earnings with increased revenues and reduced net loss, but concerns remain over financial stability. The company focuses on expanding hematology/oncology products, showing promise in growth strategies, bu...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire First quarter 2024 total revenue of $29.5 million , which includes TAVALISSE ® net product sales of $21.1 million and REZLIDHIA ® net product sales of ...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will re...